Section_Name,Content,Approved/Disapproved,Blanks,signature,final_response,Content_modified,Category,Entity Dictionary,Final_signature
Id,Prot Specific Site IC IC Main IM011-047 USA 0253 10 Jun 2020  ,,,,,,Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Sponsor / Study Title:,"Bristol Myers Squibb/ A Multi-Center, Randomized, Double- Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to- Severe Plaque Psoriasis",,,,,,Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Address,"GCM Medical Group, PSC Urb. Floral Park 62 Calle Jose Marti San Juan, PR  00917 Puerto Rico",,,,,,Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Subject Information Sheet and Informed Consent Form,,,,yes,yes,"
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
1.0 Introduction,"Bristol-Myers Squibb Company 3401 Princeton Pike Lawrenceville, NJ 08648, USA (the Sponsor) is running a research study to see if a study drug not yet approved for market, named BMS-986165, will help in the treatment of moderate-to-severe plaque psoriasis and how safe it is to use in people.",,,yes,yes,"Bristol-Myers Squibb Company 3401 Princeton Pike Lawrenceville, NJ 08648, USA (the Sponsor) is running a research study to see if a study drug not yet approved for market, named BMS-986165, will help in the treatment of moderate-to-severe plaque psoriasis and how safe it is to use in people.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
1.0 Introduction,Clinical research studies in humans are done to find better ways to treat diseases and medical conditions. You are being considered for participation in this research study because you have moderate-to-severe plaque psoriasis.,,,yes,yes,"Clinical research studies in humans are done to find better ways to treat diseases and medical conditions. You are being considered for participation in this research study because you have moderate-to-severe plaque psoriasis.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
1.0 Introduction,"This information sheet is provided to allow you to make an informed decision on whether you would like to take part in the study. Also, your ability to be in the study will be decided based on the screening procedures described below and other eligibility criteria. This sheet gives information about why the study is being done, the study treatment, medical tests and procedures that will be done, and potential risks and possible benefits, if any, so you can make an informed decision about whether or not to be in the study. You are free to ask questions at any time and discuss this information with who you wish to help you decide. Your participation is voluntary, if you do not want to take part you do not need to do anything, and your study doctor will discuss what other treatments are available to you. If you decide not to take part in this research study, you will not lose any health care services that you would otherwise receive. If you do decide to take part, you will have to sign and date the consent form, but you can still withdraw your consent at any time. You will receive a copy of the signed and dated consent form.",,,yes,yes,"This information sheet is provided to allow you to make an informed decision on whether you would like to take part in the study. Also, your ability to be in the study will be decided based on the screening procedures described below and other eligibility criteria. This sheet gives information about why the study is being done, the study treatment, medical tests and procedures that will be done, and potential risks and possible benefits, if any, so you can make an informed decision about whether or not to be in the study. You are free to ask questions at any time and discuss this information with who you wish to help you decide. Your participation is voluntary, if you do not want to take part you do not need to do anything, and your study doctor will discuss what other treatments are available to you. If you decide not to take part in this research study, you will not lose any health care services that you would otherwise receive. If you do decide to take part, you will have to sign and date the consent form, but you can still withdraw your consent at any time. You will receive a copy of the signed and dated consent form.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,"The study is planned to involve 1000 people (men and women aged greater than or equal to 18 years) who have moderate-to-severe plaque psoriasis. Psoriasis is a chronic inflammatory skin disorder, characterized primarily by scaly plaques, that affects up to 3% of the general population.",,,yes,yes,"The study is planned to involve 1000 people (men and women aged greater than or equal to 18 years) who have moderate-to-severe plaque psoriasis. Psoriasis is a chronic inflammatory skin disorder, characterized primarily by scaly plaques, that affects up to 3% of the general population.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,"The purpose of this study is to measure how safe and effective BMS-986165 is in treating participants with psoriasis. Other research studies in animals and in humans showed that BMS-986165 may help control the immune system that is responsible for the signs and symptoms of psoriasis by controlling the molecules in the body responsible for inflammation within the skin. In addition, blood samples will be collected to assess how the study treatments affect your body and may be used to better understand psoriasis, associated medical conditions, or who may respond to the study treatments. These biomarker samples will be used to measure things like: proteins, fats, RNA and DNA.",,,yes,yes,"The purpose of this study is to measure how safe and effective BMS-986165 is in treating participants with psoriasis. Other research studies in animals and in humans showed that BMS-986165 may help control the immune system that is responsible for the signs and symptoms of psoriasis by controlling the molecules in the body responsible for inflammation within the skin. In addition, blood samples will be collected to assess how the study treatments affect your body and may be used to better understand psoriasis, associated medical conditions, or who may respond to the study treatments. These biomarker samples will be used to measure things like: proteins, fats, RNA and DNA.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,"Your study doctor will explain when, how often and how to take the study drugs(s). BMS-986165 is an investigational drug. This means that it has not been approved by the Food and Drug Administration (FDA) for use in your disease in your country.",,,yes,yes,"Your study doctor will explain when, how often and how to take the study drugs(s). BMS-986165 is an investigational drug. This means that it has not been approved by the Food and Drug Administration (FDA) for use in your disease in your country.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,"Sometimes it is not known which way of treating people is best. To find out, researchers need to compare different treatments in research studies. The study will have three groups of participants who will receive either BMS-986165, placebo or apremilast; as a result, you may receive a placebo, which contains no active ingredient; you may receive apremilast which is approved for treatment of moderate-to-severe plaque psoriasis or you may receive BMS-986165.",,,yes,yes,"Sometimes it is not known which way of treating people is best. To find out, researchers need to compare different treatments in research studies. The study will have three groups of participants who will receive either BMS-986165, placebo or apremilast; as a result, you may receive a placebo, which contains no active ingredient; you may receive apremilast which is approved for treatment of moderate-to-severe plaque psoriasis or you may receive BMS-986165.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,"The group you are in will be selected at random. You will have a 1 in 2 chance of receiving the BMS- 986165, a 1 in 4 chance of receiving apremilast and a 1 in 4 chance of receiving placebo; these are, referred to as Ã¢ÂÂstudy treatmentÃ¢ÂÂ for the rest of this information sheet.",,,yes,yes,"The group you are in will be selected at random. You will have a 1 in 2 chance of receiving the BMS- 986165, a 1 in 4 chance of receiving apremilast and a 1 in 4 chance of receiving placebo; these are, referred to as Ã¢ÂÂstudy treatmentÃ¢ÂÂ for the rest of this information sheet.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,In this study neither you nor your study doctor will know what study treatment you are receiving.,,,yes,yes,"In this study neither you nor your study doctor will know what study treatment you are receiving.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,"The groups each have the different study treatments in turn. There may be a break between study treatments so that the first study drugs(s) are cleared from your body before you start the new study treatment. For example, you may receive the BMS-986165, placebo or apremilast for a period and then receive the other study treatment.",,,yes,yes,"The groups each have the different study treatments in turn. There may be a break between study treatments so that the first study drugs(s) are cleared from your body before you start the new study treatment. For example, you may receive the BMS-986165, placebo or apremilast for a period and then receive the other study treatment.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,"You will receive study treatment at one of the following doses, however you may not remain on the same study treatment for the full duration of the study:",,,yes,yes,"You will receive study treatment at one of the following doses, however you may not remain on the same study treatment for the full duration of the study:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,Bullet- BMS-986165 (6 mg),,,yes,yes,"Bullet- BMS-986165 (6 mg)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,Bullet- Placebo,,,yes,yes,"Bullet- Placebo
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
2.0 Study Design,Bullet- Apremilast (30 mg),,,yes,yes,"Bullet- Apremilast (30 mg)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,Your participation in the study would last 60 weeks as follows:,,,yes,yes,"Your participation in the study would last 60 weeks as follows:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,Bullet- screening (up to 4 weeks),,,yes,yes,"Bullet- screening (up to 4 weeks)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,Bullet- study treatment (24 weeks),,,yes,yes,"Bullet- study treatment (24 weeks)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,Bullet- re-assignment to study treatment group (which could include placebo treatment) (28 weeks),,,yes,yes,"Bullet- re-assignment to study treatment group (which could include placebo treatment) (28 weeks)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,Bullet- follow up (4 weeks),,,yes,yes,"Bullet- follow up (4 weeks)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,"This will involve visits to your study doctor every four weeks for a total of 18 visits. You will receive study treatment for a total of 52 weeks, at the end of study treatment the study doctor will continue to monitor you for four weeks as part of a safety follow up.",,,yes,yes,"This will involve visits to your study doctor every four weeks for a total of 18 visits. You will receive study treatment for a total of 52 weeks, at the end of study treatment the study doctor will continue to monitor you for four weeks as part of a safety follow up.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,You will also be asked to complete approximately seven questionnaires throughout the study and a study diary each day. Some of these you will complete on paper or on an electronic device; these questionnaires can take a little while to complete and you should be willing to take the time to complete them to ensure your study doctor has accurate information about your psoriasis.,,,yes,yes,"You will also be asked to complete approximately seven questionnaires throughout the study and a study diary each day. Some of these you will complete on paper or on an electronic device; these questionnaires can take a little while to complete and you should be willing to take the time to complete them to ensure your study doctor has accurate information about your psoriasis.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Activities and Time Commitment,"Bristol-Myers Squibb Company will also run a long-term extension study which you may be eligible to take part in. The study will be two years or longer, please speak to your study doctor for more information.",,,yes,yes,"Bristol-Myers Squibb Company will also run a long-term extension study which you may be eligible to take part in. The study will be two years or longer, please speak to your study doctor for more information.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"After you voluntarily agree to participate in this study, and before starting any study-related procedures, you will be asked to sign and date this Informed Consent Form. After you consent to the study, you will have tests done to see if you meet criteria to be in the study. Some of these tests and/or procedures are part of regular care and may be done even if you do not take part in the study. If you have had some of them recently, they may not need to be repeated. This decision will be up to your study doctor. This process is known as the Screening Period. The Screening Period will determine whether or not you can receive the study treatment.",,,yes,yes,"After you voluntarily agree to participate in this study, and before starting any study-related procedures, you will be asked to sign and date this Informed Consent Form. After you consent to the study, you will have tests done to see if you meet criteria to be in the study. Some of these tests and/or procedures are part of regular care and may be done even if you do not take part in the study. If you have had some of them recently, they may not need to be repeated. This decision will be up to your study doctor. This process is known as the Screening Period. The Screening Period will determine whether or not you can receive the study treatment.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"If you are suitable to take part in the study, you will be asked to come back for the further visits and will have some further procedures and tests (including taking blood and urine samples). In total 513 ml or approximately 87 teaspoons of blood will be taken during the study. Your samples will be tested by Q2 Solutions 27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA and will be stored for 15 years after completion of the study.",,,yes,yes,"If you are suitable to take part in the study, you will be asked to come back for the further visits and will have some further procedures and tests (including taking blood and urine samples). In total 513 ml or approximately 87 teaspoons of blood will be taken during the study. Your samples will be tested by Q2 Solutions 27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA and will be stored for 15 years after completion of the study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"If you are a woman capable of having children, you will be required to have a pregnancy test to make sure you are not pregnant.",,,yes,yes,"If you are a woman capable of having children, you will be required to have a pregnancy test to make sure you are not pregnant.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,The screening will be completed within 28 days of signing and dating this Informed Consent Form. The Screening Period will include the following:,,,yes,yes,"The screening will be completed within 28 days of signing and dating this Informed Consent Form. The Screening Period will include the following:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Review of eligibility for this trial,,,yes,yes,"Bullet- Review of eligibility for this trial
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Medical history,,,yes,yes,"Bullet- Medical history
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Review of smoking history,,,yes,yes,"Bullet- Review of smoking history
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Physical examination,,,yes,yes,"Bullet- Physical examination
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"Bullet- Review of medications you are taking, your medication history, and when you have stopped prior medications",,,yes,yes,"Bullet- Review of medications you are taking, your medication history, and when you have stopped prior medications
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"Bullet- Vital signs - blood pressure, breathing rate, heart rate, and temperature",,,yes,yes,"Bullet- Vital signs - blood pressure, breathing rate, heart rate, and temperature
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Weight and height,,,yes,yes,"Bullet- Weight and height
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Electrocardiogram Ã¢ÂÂ(ECG) Ã¢ÂÂ exam to measure the electrical activity of your heart,,,yes,yes,"Bullet- Electrocardiogram Ã¢ÂÂ(ECG) Ã¢ÂÂ exam to measure the electrical activity of your heart
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Chest x-ray or CT (if you have not had this within 6 months),,,yes,yes,"Bullet- Chest x-ray or CT (if you have not had this within 6 months)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Concomitant medication use (discussion about medications that are allowed to take during the study),,,yes,yes,"Bullet- Concomitant medication use (discussion about medications that are allowed to take during the study)
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Assessment of neuropsychiatric history including depression and suicidal thoughts and behaviors,,,yes,yes,"Bullet- Assessment of neuropsychiatric history including depression and suicidal thoughts and behaviors
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Blood and urine samples will be taken for laboratory tests.,,,yes,yes,"Bullet- Blood and urine samples will be taken for laboratory tests.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"Bullet- Blood samples including testing for tuberculosis, thyroid activity and checking your antibody levels in the blood to help measure the status of your immune system.",,,yes,yes,"Bullet- Blood samples including testing for tuberculosis, thyroid activity and checking your antibody levels in the blood to help measure the status of your immune system.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"Please note that your blood will be tested for hepatitis and human immunodeficiency virus (HBV and HCV, and HIV). Positive results for these infectious diseases will be reported by the study doctor to the appropriate authority as required by law if applicable in your country. If you have any questions regarding hepatitis and HIV testing please ask your study doctor.",,,yes,yes,"Please note that your blood will be tested for hepatitis and human immunodeficiency virus (HBV and HCV, and HIV). Positive results for these infectious diseases will be reported by the study doctor to the appropriate authority as required by law if applicable in your country. If you have any questions regarding hepatitis and HIV testing please ask your study doctor.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Tuberculosis test,,,yes,yes,"Bullet- Tuberculosis test
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Pregnancy blood test for women of childbearing potential,,,yes,yes,"Bullet- Pregnancy blood test for women of childbearing potential
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- FSH (hormone) measurement for women,,,yes,yes,"Bullet- FSH (hormone) measurement for women
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Urine test,,,yes,yes,"Bullet- Urine test
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,Bullet- Assessment of the severity of your psoriasis and a questionnaire,,,yes,yes,"Bullet- Assessment of the severity of your psoriasis and a questionnaire
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"Bullet- You will also be asked to complete a daily diary to record your signs and symptoms. This may be a paper-based diary or may be electronic Ã¢ÂÂ if electronic, the device you are given to complete your diary with should be returned to your study doctor when no longer needed.",,,yes,yes,"Bullet- You will also be asked to complete a daily diary to record your signs and symptoms. This may be a paper-based diary or may be electronic Ã¢ÂÂ if electronic, the device you are given to complete your diary with should be returned to your study doctor when no longer needed.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Screening Period,"If you happen to not meet all the criteria to take part in the study at screening or randomization and have not been treated with disallowed medications, you may be rescreened. In this case you must re-consent and will be assigned a new identification number, and the full screening period will be performed again.",,,yes,yes,"If you happen to not meet all the criteria to take part in the study at screening or randomization and have not been treated with disallowed medications, you may be rescreened. In this case you must re-consent and will be assigned a new identification number, and the full screening period will be performed again.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Period,"If you meet the study requirements and you choose to continue to take part, you will enter the Study Period. You will be put into a study group to receive study treatment with BMS-986165, placebo or apremilast.",,,yes,yes,"If you meet the study requirements and you choose to continue to take part, you will enter the Study Period. You will be put into a study group to receive study treatment with BMS-986165, placebo or apremilast.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Period,"Weeks 0 to 24 are the part of the study which compares a treatment known to be effective to the other study treatments; in this period the effects of BMS-986165, placebo or apremilast are compared. You may receive any of these three study treatments as defined above in section 2.0.",,,yes,yes,"Weeks 0 to 24 are the part of the study which compares a treatment known to be effective to the other study treatments; in this period the effects of BMS-986165, placebo or apremilast are compared. You may receive any of these three study treatments as defined above in section 2.0.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Period,"Some of the activities will require you to fast in advance of blood being taken, this will require you not to consume any food or drink except water for at least 10 hours before sample collection. Your study doctor will discuss this with you.",,,yes,yes,"Some of the activities will require you to fast in advance of blood being taken, this will require you not to consume any food or drink except water for at least 10 hours before sample collection. Your study doctor will discuss this with you.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Please see Table 1 below for the list of activities at each visit during week 0 to week 20.,Weeks 24 to 52 may include your re-assignment to a different study treatment group (which could include placebo treatment); you may receive the same study treatment as in weeks 0 to 20 or a different study treatment for this part of the study.,,,yes,yes,"Weeks 24 to 52 may include your re-assignment to a different study treatment group (which could include placebo treatment); you may receive the same study treatment as in weeks 0 to 20 or a different study treatment for this part of the study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Please see Table 2 below for the list of activities at each visit during week 24 to week 52.,The study doctor/staff will explain the details and provide specific instructions about each of the procedures needed.,,,yes,yes,"The study doctor/staff will explain the details and provide specific instructions about each of the procedures needed.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Please see Table 2 below for the list of activities at each visit during week 24 to week 52.,An average of approximately 28 mL (5 teaspoons) up to a maximum of 62 mL (10.5 teaspoons) will be taken at each visit (including screening and follow up visits). The total amount of blood collected during this trial is about 513 mL (approximately 87 teaspoons or 29 tablespoons).,,,yes,yes,"An average of approximately 28 mL (5 teaspoons) up to a maximum of 62 mL (10.5 teaspoons) will be taken at each visit (including screening and follow up visits). The total amount of blood collected during this trial is about 513 mL (approximately 87 teaspoons or 29 tablespoons).
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Table 1 Study Period: Week 0 to Week 20,Table 2 Study Period: Week 24 to Week 52,,,yes,yes,"Table 2 Study Period: Week 24 to Week 52
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Follow-up Period,"When you stop or complete study treatments you will begin the last part of the study, the follow-up period. During this period your study doctor will continue to assess your health condition. It is important to know, for example, if you have recovered, developed an illness or suffered an important adverse event.",,,yes,yes,"When you stop or complete study treatments you will begin the last part of the study, the follow-up period. During this period your study doctor will continue to assess your health condition. It is important to know, for example, if you have recovered, developed an illness or suffered an important adverse event.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Follow-up Period,"The follow-up period includes one visit at week 56 of the study. The follow up visit will include physical examination, body weight and vital signs, review of adverse events and your other medications, Blood and urine collection for laboratory tests (hematology, clinical chemistry and urinalysis) and a urine test for pregnancy if you are female. The follow-up visit should last no longer than your other study visits.",,,yes,yes,"The follow-up period includes one visit at week 56 of the study. The follow up visit will include physical examination, body weight and vital signs, review of adverse events and your other medications, Blood and urine collection for laboratory tests (hematology, clinical chemistry and urinalysis) and a urine test for pregnancy if you are female. The follow-up visit should last no longer than your other study visits.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Follow-up Period,"Please note that if the study doctor thinks it is necessary, you may be asked to come for additional visits or assessments for your safety.",,,yes,yes,"Please note that if the study doctor thinks it is necessary, you may be asked to come for additional visits or assessments for your safety.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Follow-up Period,"If it is necessary to further test the safety or effectiveness of the study treatment, it may be necessary to have access to additional information about your health status. Your study doctor may attempt to obtain study-related information about your health from you or from other sources, including your primary care doctor and public sources such as national patient registries (for example, cancer registries). This may include contacting you again by phone or letter.",,,yes,yes,"If it is necessary to further test the safety or effectiveness of the study treatment, it may be necessary to have access to additional information about your health status. Your study doctor may attempt to obtain study-related information about your health from you or from other sources, including your primary care doctor and public sources such as national patient registries (for example, cancer registries). This may include contacting you again by phone or letter.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
If Your Study Doctor Cannot Locate You,"If your study doctor needs to follow up with you but cannot find you, he/she may try to learn your new address, telephone number or current health status by calling or writing to the person(s) named as your secondary contacts. If your study doctor cannot obtain information through your secondary contacts, he or she may ask for the assistance of a third-party representative and may share with that representative limited information about you, such as your name and last known address. The representative will consult public sources, such as public health registries and databases, to obtain your current contact information. The representative will only share this information with the study doctor, to help him/her complete the follow-up stage of the trial. Only the study doctor or a member of his/her team will contact you or your family members.",,,yes,yes,"If your study doctor needs to follow up with you but cannot find you, he/she may try to learn your new address, telephone number or current health status by calling or writing to the person(s) named as your secondary contacts. If your study doctor cannot obtain information through your secondary contacts, he or she may ask for the assistance of a third-party representative and may share with that representative limited information about you, such as your name and last known address. The representative will consult public sources, such as public health registries and databases, to obtain your current contact information. The representative will only share this information with the study doctor, to help him/her complete the follow-up stage of the trial. Only the study doctor or a member of his/her team will contact you or your family members.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Medication Discontinuation Requirements,"For this study, some of the medications that you may have recently used will need to have been stopped for certain periods of time before you can take part in the study. Your study doctor will discuss the medications you have taken and advise you if you need to discontinue them for longer periods before signing and dating consent to be in this study.",,,yes,yes,"For this study, some of the medications that you may have recently used will need to have been stopped for certain periods of time before you can take part in the study. Your study doctor will discuss the medications you have taken and advise you if you need to discontinue them for longer periods before signing and dating consent to be in this study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Study Treatment After the End of the Study,"At the end of the study, the study doctor will ensure that you continue to receive appropriate health care services to treat your psoriasis. In addition, for participants who continue to demonstrate clinical benefit, Bristol-Myers Squibb Company may continue to provide study treatment via an extension of the current study, a rollover study requiring approval by responsible health authority and ethics committee, or through another mechanism at the discretion of BMS where acceptable with local laws.",,,yes,yes,"At the end of the study, the study doctor will ensure that you continue to receive appropriate health care services to treat your psoriasis. In addition, for participants who continue to demonstrate clinical benefit, Bristol-Myers Squibb Company may continue to provide study treatment via an extension of the current study, a rollover study requiring approval by responsible health authority and ethics committee, or through another mechanism at the discretion of BMS where acceptable with local laws.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
4.0 Biological samples,"This study involves the collection of biological samples, such as blood and urine as described under section 3 Ã¢ÂÂStudy Activities and Time CommitmentÃ¢ÂÂ. Your samples will be shipped to an accredited central laboratory and will be stored there awaiting analysis. The central laboratory being used in this study is Q2 Solutions 27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA. Biomarker samples will be retained for a minimum of 15 years following the completion of the clinical study report to allow sufficient time to complete biomarker studies. Other samples will be destroyed once all the laboratory tests have been completed except if you agree to the retention of samples for additional research. In that case, please tick the relevant box in the informed consent form below about the additional research.",,,yes,yes,"This study involves the collection of biological samples, such as blood and urine as described under section 3 Ã¢ÂÂStudy Activities and Time CommitmentÃ¢ÂÂ. Your samples will be shipped to an accredited central laboratory and will be stored there awaiting analysis. The central laboratory being used in this study is Q2 Solutions 27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA. Biomarker samples will be retained for a minimum of 15 years following the completion of the clinical study report to allow sufficient time to complete biomarker studies. Other samples will be destroyed once all the laboratory tests have been completed except if you agree to the retention of samples for additional research. In that case, please tick the relevant box in the informed consent form below about the additional research.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
4.0 Biological samples,"You can ask in writing for your samples to be destroyed at any time. However, data already derived from your samples will continue to be kept and used for the purposes described in this document. Your data will be protected by a code that will not allow BMS or its third parties to know your identity. If you decide to leave the study at any time but do not ask for your samples to be destroyed, BMS may continue to use your samples for the purposes described in this document.",,,yes,yes,"You can ask in writing for your samples to be destroyed at any time. However, data already derived from your samples will continue to be kept and used for the purposes described in this document. Your data will be protected by a code that will not allow BMS or its third parties to know your identity. If you decide to leave the study at any time but do not ask for your samples to be destroyed, BMS may continue to use your samples for the purposes described in this document.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Biomarker Testing Being Done in this Study,"During the course of this study, researchers may run biomarker tests on the samples being collected to answer the questions being asked in this study. Biomarkers include proteins, RNA, and other molecules which can be found in blood, other body fluids, or tissues. Biomarker tests can aid in understanding how or if a body will respond to a treatment and predicting how a disease will progress. These tests may also help in understanding the pathways and organs associated with the disease being studied.",,,yes,yes,"During the course of this study, researchers may run biomarker tests on the samples being collected to answer the questions being asked in this study. Biomarkers include proteins, RNA, and other molecules which can be found in blood, other body fluids, or tissues. Biomarker tests can aid in understanding how or if a body will respond to a treatment and predicting how a disease will progress. These tests may also help in understanding the pathways and organs associated with the disease being studied.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Biomarker Testing Being Done in this Study,"During the course of this study, researchers would also like to run testing on your samples that looks at some or all of your DNA. This can also aid in understanding how or if a body will respond to the study treatment(s) and predicting how the disease may progress. These tests may also help in understanding the pathways and organs associated with the disease being studied. This testing is not required in order to participate in this study. Please refer to Patient Informed Consent signature page to select your option.",,,yes,yes,"During the course of this study, researchers would also like to run testing on your samples that looks at some or all of your DNA. This can also aid in understanding how or if a body will respond to the study treatment(s) and predicting how the disease may progress. These tests may also help in understanding the pathways and organs associated with the disease being studied. This testing is not required in order to participate in this study. Please refer to Patient Informed Consent signature page to select your option.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Biomarker Testing Being Done in this Study,The information from these tests may also be used to create or improve tests that may help predict how study participants and their disease are responding to study treatment or to help choose the right drug for participants. The information from these tests may also be used to inform new studies as they are developed in the future.,,,yes,yes,"The information from these tests may also be used to create or improve tests that may help predict how study participants and their disease are responding to study treatment or to help choose the right drug for participants. The information from these tests may also be used to inform new studies as they are developed in the future.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Biomarker Testing Being Done in this Study,"The purpose of this biomarker testing is to study the effects of BMS-986165 on the body and to learn more about the psoriasis, autoimmunity, and associated medical conditions under study. The work may involve all aspects or possible causes of these diseases and conditions, including but not limited to inflammation, autoimmunity, liver inflammation and scarring, cardiovascular health, and metabolic syndrome pathways (fibrosis, obesity, diabetes mellitus, heart disease).",,,yes,yes,"The purpose of this biomarker testing is to study the effects of BMS-986165 on the body and to learn more about the psoriasis, autoimmunity, and associated medical conditions under study. The work may involve all aspects or possible causes of these diseases and conditions, including but not limited to inflammation, autoimmunity, liver inflammation and scarring, cardiovascular health, and metabolic syndrome pathways (fibrosis, obesity, diabetes mellitus, heart disease).
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Biomarker Testing Being Done in this Study,The samples collected during this study will be used for the purposes described in this section throughout their usable life and will be destroyed at the end of the scheduled storage period which will be no longer than fifteen (15) years after the end of the study or the maximum allowed by applicable law.,,,yes,yes,"The samples collected during this study will be used for the purposes described in this section throughout their usable life and will be destroyed at the end of the scheduled storage period which will be no longer than fifteen (15) years after the end of the study or the maximum allowed by applicable law.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Biomarker Testing Being Done in this Study,All of the biomarker testing described here is different from Additional Research which may be described later in this consent.,,,yes,yes,"All of the biomarker testing described here is different from Additional Research which may be described later in this consent.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Biomarker Testing Being Done in this Study,"This information will be kept confidential as outlined in this informed consent. Individual subject results of biomarker assessments will not be shared, but group information may be shared.",,,yes,yes,"This information will be kept confidential as outlined in this informed consent. Individual subject results of biomarker assessments will not be shared, but group information may be shared.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
5.0 Risks,"Some procedures that will be done during the study may carry some risks, these are given below, and your study doctor can provide more information to you.",,,yes,yes,"Some procedures that will be done during the study may carry some risks, these are given below, and your study doctor can provide more information to you.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
5.0 Risks,"In addition to the risks listed below, there may be risks or side effects related to the study treatment or other study procedures that are unexpected or unknown at this time. Let your study doctor know if you experience any change in your condition or any side effects, even those which are not mentioned in this Information Sheet.",,,yes,yes,"In addition to the risks listed below, there may be risks or side effects related to the study treatment or other study procedures that are unexpected or unknown at this time. Let your study doctor know if you experience any change in your condition or any side effects, even those which are not mentioned in this Information Sheet.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
5.0 Risks,"If new information on the study treatment becomes available that may affect your decision to continue to take part in the study, your study doctor or study nurse will inform you.",,,yes,yes,"If new information on the study treatment becomes available that may affect your decision to continue to take part in the study, your study doctor or study nurse will inform you.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
6.0 Possible Side Effects,"We do not know all the possible side effects of the study treatments (BMS-986165, placebo and apremilast). Like all drugs, the study treatment(s) can cause side effects, although not everybody gets them. Most side effects are mild to moderate. However, some people may experience serious side effects and may require treatment.",,,yes,yes,"We do not know all the possible side effects of the study treatments (BMS-986165, placebo and apremilast). Like all drugs, the study treatment(s) can cause side effects, although not everybody gets them. Most side effects are mild to moderate. However, some people may experience serious side effects and may require treatment.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
6.0 Possible Side Effects,The following side effects have been experienced by other people who have taken the study treatment(s).,,,yes,yes,"The following side effects have been experienced by other people who have taken the study treatment(s).
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,BMS-986165 is an investigational drug that is being tested in research studies and is not an approved medicine to treat any condition.,,,yes,yes,"BMS-986165 is an investigational drug that is being tested in research studies and is not an approved medicine to treat any condition.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,"Overall, approximately 774 healthy participants or participants with psoriasis have across 14 research studies received one dose or multiple doses of the study treatment BMS-986165, comparator treatment of placebo. In these studies, most of the side effects were mild or moderate in intensity. In a few cases, side effects were serious and required hospitalization.",,,yes,yes,"Overall, approximately 774 healthy participants or participants with psoriasis have across 14 research studies received one dose or multiple doses of the study treatment BMS-986165, comparator treatment of placebo. In these studies, most of the side effects were mild or moderate in intensity. In a few cases, side effects were serious and required hospitalization.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,"In the research study of BMS-986165 which you are considering, the highest dose level will be 6 mg.",,,yes,yes,"In the research study of BMS-986165 which you are considering, the highest dose level will be 6 mg.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,"The side effects in the tables below are based on unblinded information (i.e., the actual study treatment is given known) about side effects observed in 276 healthy participants or participants with psoriasis who got multiple doses of BMS-986165 were multiple doses of BMS-986165 alone up to a maximum dose of 12 mg daily. The side effects are categorized as very common or common based on how frequently they occurred.",,,yes,yes,"The side effects in the tables below are based on unblinded information (i.e., the actual study treatment is given known) about side effects observed in 276 healthy participants or participants with psoriasis who got multiple doses of BMS-986165 were multiple doses of BMS-986165 alone up to a maximum dose of 12 mg daily. The side effects are categorized as very common or common based on how frequently they occurred.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,"All of the possible discomforts, side effects, and risks related to receiving BMS-986165 are not known. You could have additional side effects with this study treatment.",,,yes,yes,"All of the possible discomforts, side effects, and risks related to receiving BMS-986165 are not known. You could have additional side effects with this study treatment.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,"Participants who take BMS-986165 may have a higher chance of infections. Call your study doctor right away if you have the following symptoms because they may be early signs of a serious infection: fever, feeling very tired, having a cough, feeling like you have the flu, warm, red, or painful skin, burning sensation during urination.",,,yes,yes,"Participants who take BMS-986165 may have a higher chance of infections. Call your study doctor right away if you have the following symptoms because they may be early signs of a serious infection: fever, feeling very tired, having a cough, feeling like you have the flu, warm, red, or painful skin, burning sensation during urination.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,Talk to your study doctor about your vaccination plans. You should not have received a live vaccine within 2 months before starting study treatment. or for 2 months after taking the last dose of study treatment. Study treatment BMS-986165 may cause some vaccines to be less effective if taken during treatment period.,,,yes,yes,"Talk to your study doctor about your vaccination plans. You should not have received a live vaccine within 2 months before starting study treatment. or for 2 months after taking the last dose of study treatment. Study treatment BMS-986165 may cause some vaccines to be less effective if taken during treatment period.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
BMS-986165,"Side effects of the study treatment when taken with other medications has been looked at in research studies according to US and European Union guidelines. Based on those studies and what we know about how the body handles the study treatment, the chance for interactions with other medications is low.",,,yes,yes,"Side effects of the study treatment when taken with other medications has been looked at in research studies according to US and European Union guidelines. Based on those studies and what we know about how the body handles the study treatment, the chance for interactions with other medications is low.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Apremilast (OTEZLA ÃÂ®),Apremilast is approved for the treatment of patients with moderate to severe plaque psoriasis.,,,yes,yes,"Apremilast is approved for the treatment of patients with moderate to severe plaque psoriasis.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Apremilast (OTEZLA ÃÂ®),"Like all medicines, this medicine can cause side effects, although not everybody gets them. In the research study which you are considering, the highest dose level of apremilast will be 30 mg taken two times each day. Patients taking apremilast at a dose level of 30 mg two times each day should be aware of the side effects listed below. The side effects are categorized as very common or common based on how frequently they occurred.",,,yes,yes,"Like all medicines, this medicine can cause side effects, although not everybody gets them. In the research study which you are considering, the highest dose level of apremilast will be 30 mg taken two times each day. Patients taking apremilast at a dose level of 30 mg two times each day should be aware of the side effects listed below. The side effects are categorized as very common or common based on how frequently they occurred.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Apremilast (OTEZLA ÃÂ®),"There have been reports of severe diarrhea, nausea, and vomiting as side effects. Most occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years old or older and patients taking medications that can lead to dehydration or low blood pressure may be at a higher risk of complications from severe diarrhea, nausea, or vomiting.",,,yes,yes,"There have been reports of severe diarrhea, nausea, and vomiting as side effects. Most occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years old or older and patients taking medications that can lead to dehydration or low blood pressure may be at a higher risk of complications from severe diarrhea, nausea, or vomiting.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Apremilast (OTEZLA ÃÂ®),Treatment with apremilast is associated with an increase in depression. You or your caregiver should immediately inform your doctor of any changes in behavior or mood and of any suicidal thoughts you may have and you may be referred to a mental health professional.,,,yes,yes,"Treatment with apremilast is associated with an increase in depression. You or your caregiver should immediately inform your doctor of any changes in behavior or mood and of any suicidal thoughts you may have and you may be referred to a mental health professional.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Apremilast (OTEZLA ÃÂ®),"Weight loss can occur as a side effect of apremilast. In research studies, weight loss up to 10% of body weight occurred more often in participants treated with apremilast than with placebo.",,,yes,yes,"Weight loss can occur as a side effect of apremilast. In research studies, weight loss up to 10% of body weight occurred more often in participants treated with apremilast than with placebo.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Apremilast (OTEZLA ÃÂ®),"All of the possible discomforts, side effects, and risks related to receiving treatment with apremilast are not known. You could have additional side effects with this treatment.",,,yes,yes,"All of the possible discomforts, side effects, and risks related to receiving treatment with apremilast are not known. You could have additional side effects with this treatment.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
7.0 Cautions and Warnings,,,,yes,yes,"
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
"Since BMS-986165 is a research medicine, there may be other risks that are yet unknown. All medicines have the potential risk of an allergic reaction, which, if not treated promptly, could become life threatening. You should seek medical help right away if you think you have any of the following symptoms of a serious allergic reaction: trouble breathing or swelling of the face, mouth, lips, gums, tongue or neck. Other symptoms of an allergic reaction may include rash, hives, or blisters.","It is important that you tell the study doctor about any negative changes in your health as soon as they occur, whether or not you think they are caused by the study treatment.",,,yes,yes,"It is important that you tell the study doctor about any negative changes in your health as soon as they occur, whether or not you think they are caused by the study treatment.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
"Since BMS-986165 is a research medicine, there may be other risks that are yet unknown. All medicines have the potential risk of an allergic reaction, which, if not treated promptly, could become life threatening. You should seek medical help right away if you think you have any of the following symptoms of a serious allergic reaction: trouble breathing or swelling of the face, mouth, lips, gums, tongue or neck. Other symptoms of an allergic reaction may include rash, hives, or blisters.",All study treatment must be taken only by the person for whom it has been prescribed.,,,yes,yes,"All study treatment must be taken only by the person for whom it has been prescribed.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
8.0 Potential Benefits,"There is no guarantee that you will receive any benefit from taking part in this study. Your condition may remain the same, improve or could get worse. Information obtained from the study may help in the development of better treatments for moderate-to-severe plaque psoriasis. The information we get from this study may help improve the treatment of people with psoriasis.",,,yes,yes,"There is no guarantee that you will receive any benefit from taking part in this study. Your condition may remain the same, improve or could get worse. Information obtained from the study may help in the development of better treatments for moderate-to-severe plaque psoriasis. The information we get from this study may help improve the treatment of people with psoriasis.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
9.0 Information for Women of Childbearing Potential (Pregnancy/Birth Control),"BMS-986165 has been studied in laboratory and animal experiments to see if it causes problems with pregnancy or birth defects. However, even when the results are all normal, the risks to pregnant women or an unborn baby of taking BMS-986165 are unknown. Apremilast has not been adequately examined in well controlled studies in pregnant women and the incidences of malformations and pregnancy loss in human pregnancies have not been established. The effects of apremilast on labor and delivery in pregnant women are unknown as well. For these reasons, women must have a negative serum pregnancy test before the study starts and again just before receiving BMS-986165. Urine pregnancy tests will be done monthly throughout the study and must remain negative.",,,yes,yes,"BMS-986165 has been studied in laboratory and animal experiments to see if it causes problems with pregnancy or birth defects. However, even when the results are all normal, the risks to pregnant women or an unborn baby of taking BMS-986165 are unknown. Apremilast has not been adequately examined in well controlled studies in pregnant women and the incidences of malformations and pregnancy loss in human pregnancies have not been established. The effects of apremilast on labor and delivery in pregnant women are unknown as well. For these reasons, women must have a negative serum pregnancy test before the study starts and again just before receiving BMS-986165. Urine pregnancy tests will be done monthly throughout the study and must remain negative.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
9.0 Information for Women of Childbearing Potential (Pregnancy/Birth Control),"You must not become pregnant during this study and for at least 33 days after the last dose of study treatment. If you are a woman of childbearing potential, you must use an effective form of birth control during this study and 33 days after the end of study treatment.",,,yes,yes,"You must not become pregnant during this study and for at least 33 days after the last dose of study treatment. If you are a woman of childbearing potential, you must use an effective form of birth control during this study and 33 days after the end of study treatment.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
9.0 Information for Women of Childbearing Potential (Pregnancy/Birth Control),"Acceptable methods of birth control include consistent use of an approved oral contraceptive (birth control pill), intravaginal, transdermal, an implantable contraceptive, or an injectable contraceptive, Intrauterine device (IUD), Intrauterine  hormone-releasing system (IUS), male or female condom with or without spermicide, diaphragm, cervical cap, or vaginal sponge with spermicide, bilateral tubal occlusion (tubes tied), vasectomized partner or abstinence.",,,yes,yes,"Acceptable methods of birth control include consistent use of an approved oral contraceptive (birth control pill), intravaginal, transdermal, an implantable contraceptive, or an injectable contraceptive, Intrauterine device (IUD), Intrauterine  hormone-releasing system (IUS), male or female condom with or without spermicide, diaphragm, cervical cap, or vaginal sponge with spermicide, bilateral tubal occlusion (tubes tied), vasectomized partner or abstinence.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
9.0 Information for Women of Childbearing Potential (Pregnancy/Birth Control),"Oral, implantable, or injectable contraceptives are only considered effective if used properly and started at least 30 days before the screening visit. Some drugs (for example, antibiotics) may cause hormonal contraceptives to not work properly. Please inform your study doctor of all other medications you are taking. If you suspect that you may have become pregnant during the study or within 3 days of discontinuing study treatment, you must contact your study doctor immediately. The study doctor will ask for your permission to follow the progress of your pregnancy and the outcome. This information will be used to advise other women who might become pregnant while taking the study treatment. The sponsor has not set aside any funds to pay for any aspects of obstetric, child or related care and does not plan to pay for them.",,,yes,yes,"Oral, implantable, or injectable contraceptives are only considered effective if used properly and started at least 30 days before the screening visit. Some drugs (for example, antibiotics) may cause hormonal contraceptives to not work properly. Please inform your study doctor of all other medications you are taking. If you suspect that you may have become pregnant during the study or within 3 days of discontinuing study treatment, you must contact your study doctor immediately. The study doctor will ask for your permission to follow the progress of your pregnancy and the outcome. This information will be used to advise other women who might become pregnant while taking the study treatment. The sponsor has not set aside any funds to pay for any aspects of obstetric, child or related care and does not plan to pay for them.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
9.0 Information for Women of Childbearing Potential (Pregnancy/Birth Control),"The effects of BMS-986165 on a nursing infant are unknown. It is not known whether or not apremilast or its metabolites (breakdown products) are present in human milk. If; if you are breastfeeding, you cannot participate in the study.",,,yes,yes,"The effects of BMS-986165 on a nursing infant are unknown. It is not known whether or not apremilast or its metabolites (breakdown products) are present in human milk. If; if you are breastfeeding, you cannot participate in the study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
10.0 Information for Men (Male Reproduction/Birth Control),"Studies show that BMS-986165 does not harm genes nor does BMS-986165 have any effects on male rat reproductive parameters (mating, fertility, and sperm morphology), or early embryonic development of the litters sired by treated males. Studies in mice have shown that apremilast has no effect on fertility in male mice. However, sexual partner(s) of a male study participant may be exposed to the study treatment because small amounts of study treatment may be present in semen. Men who are sexually active with a woman of childbearing potential, or who is pregnant or breastfeeding must follow the instructions for contraception (use a condom) for the duration of treatment plus 3 days after the final dose of study treatment. Men must inform any and all partner(s) of their participation in a clinical drug study and the need to follow these instructions. Men should refrain from donating sperm for the duration of the study treatment plus 3 days after the final dose.",,,yes,yes,"Studies show that BMS-986165 does not harm genes nor does BMS-986165 have any effects on male rat reproductive parameters (mating, fertility, and sperm morphology), or early embryonic development of the litters sired by treated males. Studies in mice have shown that apremilast has no effect on fertility in male mice. However, sexual partner(s) of a male study participant may be exposed to the study treatment because small amounts of study treatment may be present in semen. Men who are sexually active with a woman of childbearing potential, or who is pregnant or breastfeeding must follow the instructions for contraception (use a condom) for the duration of treatment plus 3 days after the final dose of study treatment. Men must inform any and all partner(s) of their participation in a clinical drug study and the need to follow these instructions. Men should refrain from donating sperm for the duration of the study treatment plus 3 days after the final dose.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
10.0 Information for Men (Male Reproduction/Birth Control),Women of childbearing potential who are sexual partners of male study participants are to consider use of effective methods of contraception until 3 days after the end of study treatment in the male subject,,,yes,yes,"Women of childbearing potential who are sexual partners of male study participants are to consider use of effective methods of contraception until 3 days after the end of study treatment in the male subject
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
10.0 Information for Men (Male Reproduction/Birth Control),"If your partner becomes pregnant during the study, you must tell your study doctor immediately. If your partner agrees the Sponsor would like to follow the progress of your partnerÃ¢ÂÂs pregnancy and the outcome.",,,yes,yes,"If your partner becomes pregnant during the study, you must tell your study doctor immediately. If your partner agrees the Sponsor would like to follow the progress of your partnerÃ¢ÂÂs pregnancy and the outcome.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,"As a participant in this study, you have certain responsibilities. You will have to:",,,yes,yes,"As a participant in this study, you have certain responsibilities. You will have to:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Tell the study doctor everything regarding your health history,,,yes,yes,"Bullet- Tell the study doctor everything regarding your health history
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Complete all required visits to the study center,,,yes,yes,"Bullet- Complete all required visits to the study center
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Take the study treatment as instructed by your study doctor,,,yes,yes,"Bullet- Take the study treatment as instructed by your study doctor
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Follow the medication discontinue requirements;,,,yes,yes,"Bullet- Follow the medication discontinue requirements;
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Tell the study doctor of any side effects and changes or new medical problems you suffer during the study,,,yes,yes,"Bullet- Tell the study doctor of any side effects and changes or new medical problems you suffer during the study
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Tell the study doctor if you (or your partner) become pregnant,,,yes,yes,"Bullet- Tell the study doctor if you (or your partner) become pregnant
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Complete diaries or participant reported questionnaires,,,yes,yes,"Bullet- Complete diaries or participant reported questionnaires
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,Bullet- Inform the study doctor or study staff if you decide you no longer wish to participate in the study. You will be required to complete a close out visit.,,,yes,yes,"Bullet- Inform the study doctor or study staff if you decide you no longer wish to participate in the study. You will be required to complete a close out visit.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Responsibilities,.,,,yes,yes,".
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
12.0 Costs,It is not expected to cost you to participate in the study. The study treatment will be provided to you free of charge and you will not be charged for any procedure performed for this study.,,,yes,yes,"It is not expected to cost you to participate in the study. The study treatment will be provided to you free of charge and you will not be charged for any procedure performed for this study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
13.0 Compensation,"You will not be paid for your participation in the study, but you may be reimbursed for reasonable expenses such as travel cost for attending the study visits.",,,yes,yes,"You will not be paid for your participation in the study, but you may be reimbursed for reasonable expenses such as travel cost for attending the study visits.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
13.0 Compensation,The Sponsor has a contract with the study doctor/study center who will receive payment for taking part in this study.,,,yes,yes,"The Sponsor has a contract with the study doctor/study center who will receive payment for taking part in this study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
13.0 Compensation,"As a participant in this study, you will receive reimbursements of up to $50 per each completed visit (Screening, Weeks 0,1,2,4,8,12,16,20,24,28,32,36,40,44,48,52 and 56) to help support your participation in the clinical trial. You will also receive up to $45 for study treatment compliance for weeks 1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52. You will be paid directly following each completed visit.",,,yes,yes,"As a participant in this study, you will receive reimbursements of up to $50 per each completed visit (Screening, Weeks 0,1,2,4,8,12,16,20,24,28,32,36,40,44,48,52 and 56) to help support your participation in the clinical trial. You will also receive up to $45 for study treatment compliance for weeks 1,2,4,8,12,16,20,24,28,32,36,40,44,48 and 52. You will be paid directly following each completed visit.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
13.0 Compensation,Any additional travel/reimbursement costs will require further approval.,,,yes,yes,"Any additional travel/reimbursement costs will require further approval.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,"If you suffer a study-related injury, the reasonable costs of necessary medical treatment of the injury will be reimbursed to the extent these costs are not covered by your private insurance or other third party coverage. Please contact the study doctor regarding reimbursement for a study-related injury.",,,yes,yes,"If you suffer a study-related injury, the reasonable costs of necessary medical treatment of the injury will be reimbursed to the extent these costs are not covered by your private insurance or other third party coverage. Please contact the study doctor regarding reimbursement for a study-related injury.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,A study-related injury is a physical injury that is directly caused by the study drug administered as described in the study protocol.,,,yes,yes,"A study-related injury is a physical injury that is directly caused by the study drug administered as described in the study protocol.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,A Study-related injury does not include injuries directly caused by any of the following:,,,yes,yes,"A Study-related injury does not include injuries directly caused by any of the following:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,Bullet- The natural course of your underlying disease or medical condition,,,yes,yes,"Bullet- The natural course of your underlying disease or medical condition
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,Bullet- Not following the instructions provided in this consent form or by study staff,,,yes,yes,"Bullet- Not following the instructions provided in this consent form or by study staff
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,"There are no plans to provide any other payments or other forms of compensation for a study-related injury (for example, for lost wages or discomfort). You do not give up any legal rights by signing this consent form.",,,yes,yes,"There are no plans to provide any other payments or other forms of compensation for a study-related injury (for example, for lost wages or discomfort). You do not give up any legal rights by signing this consent form.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,"Medicare, Medicaid and TRICARE Beneficiaries",,,yes,yes,"Medicare, Medicaid and TRICARE Beneficiaries
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,"If you are a Medicare, Medicaid or TRICARE beneficiary, the costs of necessary medical treatment of the study-related injuries described above may not be billed to Medicare, Medicaid and TRICARE. These medical bills should be submitted first to study doctor for review and payment. Contact your study doctor if you have any questions about this restriction.",,,yes,yes,"If you are a Medicare, Medicaid or TRICARE beneficiary, the costs of necessary medical treatment of the study-related injuries described above may not be billed to Medicare, Medicaid and TRICARE. These medical bills should be submitted first to study doctor for review and payment. Contact your study doctor if you have any questions about this restriction.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,"The Sponsor has taken out an insurance policy for the study that complies with current local law. If you are injured or your health is affected the Sponsor will pay all reasonable and necessary medical costs to treat the injury or illness, if the injury or health issue was directly caused by the study treatment(s) or correctly performed study procedures.",,,yes,yes,"The Sponsor has taken out an insurance policy for the study that complies with current local law. If you are injured or your health is affected the Sponsor will pay all reasonable and necessary medical costs to treat the injury or illness, if the injury or health issue was directly caused by the study treatment(s) or correctly performed study procedures.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,"To pay medical expenses, the sponsor will need to know some information about you like your name, date of birth, and Medicare Beneficiary Identifier (MBI). This is because the sponsor has to check to see if you receive Medicare and if you do, report the payment it makes to Medicare.",,,yes,yes,"To pay medical expenses, the sponsor will need to know some information about you like your name, date of birth, and Medicare Beneficiary Identifier (MBI). This is because the sponsor has to check to see if you receive Medicare and if you do, report the payment it makes to Medicare.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
14.0 Compensation for Injury,"Please note that taking part in this study may affect any personal insurance policies you have, such as health insurance, and you should contact your insurer to check if this is the case.",,,yes,yes,"Please note that taking part in this study may affect any personal insurance policies you have, such as health insurance, and you should contact your insurer to check if this is the case.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
15.0 Voluntary Participation/Withdrawal,"You can choose whether you want to take part in the study and you can change your mind at any time. If you decide not to take part or stop taking part after the study has started this will not affect your future treatment and care. If you want to withdraw from the study, you should contact your study doctor or study center staff.",,,yes,yes,"You can choose whether you want to take part in the study and you can change your mind at any time. If you decide not to take part or stop taking part after the study has started this will not affect your future treatment and care. If you want to withdraw from the study, you should contact your study doctor or study center staff.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
15.0 Voluntary Participation/Withdrawal,"Your study doctor may also decide that you should no longer take part in the study if it is in your best interests or if you do not follow the instructions you receive for taking part in the study. The Sponsor,",,,yes,yes,"Your study doctor may also decide that you should no longer take part in the study if it is in your best interests or if you do not follow the instructions you receive for taking part in the study. The Sponsor,
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
15.0 Voluntary Participation/Withdrawal,Instutional Review Board or Regulatory Authority may also decide to stop the study at any time for any reason.,,,yes,yes,"Instutional Review Board or Regulatory Authority may also decide to stop the study at any time for any reason.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
15.0 Voluntary Participation/Withdrawal,"If you decide to no longer take part in the study, or your study doctor decides you should no longer take part you will be asked to attend a last visit to ensure it is safe for you to no longer be monitored by the study doctor. You will not take part in the study after withdrawal.",,,yes,yes,"If you decide to no longer take part in the study, or your study doctor decides you should no longer take part you will be asked to attend a last visit to ensure it is safe for you to no longer be monitored by the study doctor. You will not take part in the study after withdrawal.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
15.0 Voluntary Participation/Withdrawal,"Remember that Section 3 describes follow-up activities that may begin after you decide to stop study treatments. If you decide to stop study treatments, your study doctor will not presume that you have withdrawn from the study but will assume that you will continue to participate in any follow-up activities described in Section 3. If you do not want to participate in any or all follow-up activities, you must inform your study doctor in writing and clearly identify the activities you do not want.",,,yes,yes,"Remember that Section 3 describes follow-up activities that may begin after you decide to stop study treatments. If you decide to stop study treatments, your study doctor will not presume that you have withdrawn from the study but will assume that you will continue to participate in any follow-up activities described in Section 3. If you do not want to participate in any or all follow-up activities, you must inform your study doctor in writing and clearly identify the activities you do not want.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
15.0 Voluntary Participation/Withdrawal,"Please note that even if you withdraw consent for further follow-up or contacts, if the investigator becomes aware of additional safety information this will reported to the sponsor in order to comply with legal or regulatory requirements.",,,yes,yes,"Please note that even if you withdraw consent for further follow-up or contacts, if the investigator becomes aware of additional safety information this will reported to the sponsor in order to comply with legal or regulatory requirements.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
15.0 Voluntary Participation/Withdrawal,"If there is new information available on the study treatment during the study which might make you change your mind about taking part in the study, you will be informed of this new information without delay.",,,yes,yes,"If there is new information available on the study treatment during the study which might make you change your mind about taking part in the study, you will be informed of this new information without delay.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
16.0 Alternative Treatments,"If you do not wish to participate in this study, you will continue to be treated by your normal doctor and your care will not be affected in any way. Your study doctor will discuss with you other treatments, including the benefits and risks, which are available for moderate-to-severe plaque psoriasis. Approved treatments may include topical medications, systemic medications, phototherapy, or biologic medications.",,,yes,yes,"If you do not wish to participate in this study, you will continue to be treated by your normal doctor and your care will not be affected in any way. Your study doctor will discuss with you other treatments, including the benefits and risks, which are available for moderate-to-severe plaque psoriasis. Approved treatments may include topical medications, systemic medications, phototherapy, or biologic medications.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,"During the study, if you experience any medical problems, suffer a research-related injury, or have questions, concerns or complaints about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. If you seek emergency care, or hospitalization is required, alert the treating physician that you are participating in this research study.",,,yes,yes,"During the study, if you experience any medical problems, suffer a research-related injury, or have questions, concerns or complaints about the study, please contact the Investigator at the telephone number listed on the first page of this consent document. If you seek emergency care, or hospitalization is required, alert the treating physician that you are participating in this research study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,"An institutional review board (IRB) is an independent committee established to help protect the rights of research subjects. If you have any questions about your rights as a research subject, and/or concerns or complaints regarding this research study, contact:",,,yes,yes,"An institutional review board (IRB) is an independent committee established to help protect the rights of research subjects. If you have any questions about your rights as a research subject, and/or concerns or complaints regarding this research study, contact:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,Bullet- By mail:,,,yes,yes,"Bullet- By mail:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,Study Subject Adviser Advarra IRB,,,yes,yes,"Study Subject Adviser Advarra IRB
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,"6940 Columbia Gateway Drive, Suite 110",,,yes,yes,"6940 Columbia Gateway Drive, Suite 110
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,"Columbia, MD 21046",,,yes,yes,"Columbia, MD 21046
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,"Bullet- or call toll free:	877-992-4724",,,yes,yes,"Bullet- or call toll free:	877-992-4724
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,Bullet- or by email:,,,yes,yes,"Bullet- or by email:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Whom to Contact About this Study,Please reference the following number when contacting the Study Subject Adviser: Pro00028065.,,,yes,yes,"Please reference the following number when contacting the Study Subject Adviser: Pro00028065.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
18.0 Confidentiality and Data Protection,,,,yes,yes,"
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Collection of Study Data,"Your study doctor and study staff will collect information about you which is relevant to this study; specifically, information about your name, address, contact details, date of birth,, images, health, your race, ethnic origin, and your life habits and sexual life. If not applicable to the study, any of the foregoing can be deleted. This collected information about you is called Ã¢ÂÂdataÃ¢ÂÂ or Ã¢ÂÂstudy dataÃ¢ÂÂ in this document.",,,yes,yes,"Your study doctor and study staff will collect information about you which is relevant to this study; specifically, information about your name, address, contact details, date of birth,, images, health, your race, ethnic origin, and your life habits and sexual life. If not applicable to the study, any of the foregoing can be deleted. This collected information about you is called Ã¢ÂÂdataÃ¢ÂÂ or Ã¢ÂÂstudy dataÃ¢ÂÂ in this document.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Confidentiality of Study Data and Key-coded Data:,"For the purposes of your participation in this study and the protection of your identity, your study doctor will assign you a unique code, such as a series of numbers and/or letters. The study doctor will record the study data collected from you in a report form that uses your assigned code, not your name. This is to protect your study data by making it anonymous for most study purposes.",,,yes,yes,"For the purposes of your participation in this study and the protection of your identity, your study doctor will assign you a unique code, such as a series of numbers and/or letters. The study doctor will record the study data collected from you in a report form that uses your assigned code, not your name. This is to protect your study data by making it anonymous for most study purposes.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Confidentiality of Study Data and Key-coded Data:,The data that is recorded with your assigned code rather than your name is called Ã¢ÂÂkey-coded dataÃ¢ÂÂ. The key-coded data will be entered into the studyÃ¢ÂÂs computer database. Your study doctor will keep a confidential list linking your name to your code and only authorized persons will have access to this list. The ways in which key-coded data may be used and shared is described below.,,,yes,yes,"The data that is recorded with your assigned code rather than your name is called Ã¢ÂÂkey-coded dataÃ¢ÂÂ. The key-coded data will be entered into the studyÃ¢ÂÂs computer database. Your study doctor will keep a confidential list linking your name to your code and only authorized persons will have access to this list. The ways in which key-coded data may be used and shared is described below.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Confidentiality of Study Data and Key-coded Data:,"Some study data will identify you (such as medical records), and the ways in which this data may be used and shared is described below.",,,yes,yes,"Some study data will identify you (such as medical records), and the ways in which this data may be used and shared is described below.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,Your key-coded data may be shared with and used by the following:,,,yes,yes,"Your key-coded data may be shared with and used by the following:
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,Bullet- The study doctor and study staff,,,yes,yes,"Bullet- The study doctor and study staff
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,"Bullet- The study sponsor, its current or future research partners, collaborators, assignees, licensees or designees > and their affiliates, agents, and employees,",,,yes,yes,"Bullet- The study sponsor, its current or future research partners, collaborators, assignees, licensees or designees > and their affiliates, agents, and employees,
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,"Bullet- Other individuals and organizations that analyze or use your information in connection with these research activities, including laboratories and study sites (in the event you transfer to another study site);",,,yes,yes,"Bullet- Other individuals and organizations that analyze or use your information in connection with these research activities, including laboratories and study sites (in the event you transfer to another study site);
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,"Bullet- Domestic or foreign health authorities for example, the Food and Drug Administration (FDA),",,,yes,yes,"Bullet- Domestic or foreign health authorities for example, the Food and Drug Administration (FDA),
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,Bullet- And Institutional Review Boards (IRBs),,,yes,yes,"Bullet- And Institutional Review Boards (IRBs)
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,Bullet- Other persons required by law,,,yes,yes,"Bullet- Other persons required by law
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,Your key-coded data will be used in connection with this study and may also be used by the parties listed above:,,,yes,yes,"Your key-coded data will be used in connection with this study and may also be used by the parties listed above:
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,"Bullet- for other current or future research involving the same drug(s), the same or related health conditions, or for other relevant health research;",,,yes,yes,"Bullet- for other current or future research involving the same drug(s), the same or related health conditions, or for other relevant health research;
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,"Bullet- in support of domestic or foreign regulatory filings, for example, as part of any marketing authorization application or supplement;",,,yes,yes,"Bullet- in support of domestic or foreign regulatory filings, for example, as part of any marketing authorization application or supplement;
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,"Bullet- transferred to individuals or companies located outside of the country or region in which you reside. However, all access to the key coded data will be controlled in accordance with applicable laws and regulations. This may include written agreements that require that the data be kept confidential and secure and be used only for the purposes permitted by this consent form or applicable laws and regulations;",,,yes,yes,"Bullet- transferred to individuals or companies located outside of the country or region in which you reside. However, all access to the key coded data will be controlled in accordance with applicable laws and regulations. This may include written agreements that require that the data be kept confidential and secure and be used only for the purposes permitted by this consent form or applicable laws and regulations;
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Key-Coded Data:,"Bullet- in publications about this study but it will remain coded. Your identity will not be revealed in any compilation, study report or publication at any time.",,,yes,yes,"Bullet- in publications about this study but it will remain coded. Your identity will not be revealed in any compilation, study report or publication at any time.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"By signing and dating this form, you authorize the study doctor and their study staff to use and disclose your Protected Health Information in connection with this Study as further described in this authorization. This authorization is designed to comply with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations; namely, the Privacy Rule.",,,yes,yes,"By signing and dating this form, you authorize the study doctor and their study staff to use and disclose your Protected Health Information in connection with this Study as further described in this authorization. This authorization is designed to comply with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations; namely, the Privacy Rule.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"What is Protected Health Information? Protected Health Information or Ã¢ÂÂPHIÃ¢ÂÂ are records that identify you which are created or collected in the course of this study. This PHI may include, but is not limited to, your name, address, telephone number, date of birth, government-issued identification number, and medical records and charts, including the results of all tests and procedures performed during this study.",,,yes,yes,"What is Protected Health Information? Protected Health Information or Ã¢ÂÂPHIÃ¢ÂÂ are records that identify you which are created or collected in the course of this study. This PHI may include, but is not limited to, your name, address, telephone number, date of birth, government-issued identification number, and medical records and charts, including the results of all tests and procedures performed during this study.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"For what purposes can your PHI be used or disclosed by the study doctor or staff? Your PHI may be used or disclosed by the study doctor or staff in order to conduct this study, as necessary for your study-related treatment or payment for such treatment, to facilitate the communication of important study-related information, to allow the Institution to conduct its normal business operations, and to ensure that information relating to this study is available to the parties that need it for study purposes. Another type of disclosure may be to regulatory authorities (for example, the US Food and Drug Administration [FDA]), Institutional Review Boards or other persons required by law to properly conduct and monitor this study, including those verifying the proper collection of study data. PHI may also be used by the study doctor or staff to determine your health, vital status or contact information should you withdraw from study treatment or are lost to follow-up.",,,yes,yes,"For what purposes can your PHI be used or disclosed by the study doctor or staff? Your PHI may be used or disclosed by the study doctor or staff in order to conduct this study, as necessary for your study-related treatment or payment for such treatment, to facilitate the communication of important study-related information, to allow the Institution to conduct its normal business operations, and to ensure that information relating to this study is available to the parties that need it for study purposes. Another type of disclosure may be to regulatory authorities (for example, the US Food and Drug Administration [FDA]), Institutional Review Boards or other persons required by law to properly conduct and monitor this study, including those verifying the proper collection of study data. PHI may also be used by the study doctor or staff to determine your health, vital status or contact information should you withdraw from study treatment or are lost to follow-up.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,With whom will the study doctor and staff share your PHI? Your PHI may be shared with or accessed by the following persons or organizations:,,,yes,yes,"With whom will the study doctor and staff share your PHI? Your PHI may be shared with or accessed by the following persons or organizations:
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"Bullet- Domestic and foreign regulatory/health authorities, for examplr, the U.S. Food and Drug Agency (FDA) on behalf of the study sponsor or parties listed below",,,yes,yes,"Bullet- Domestic and foreign regulatory/health authorities, for examplr, the U.S. Food and Drug Agency (FDA) on behalf of the study sponsor or parties listed below
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,Bullet- Affiliated Institutional Review Boards or and privacy boards,,,yes,yes,"Bullet- Affiliated Institutional Review Boards or and privacy boards
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"Bullet- The study sponsor, its current or future research partners, collaborators, assignees, licensees or designees and their affiliates, agents, and employees",,,yes,yes,"Bullet- The study sponsor, its current or future research partners, collaborators, assignees, licensees or designees and their affiliates, agents, and employees
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,Bullet- Health care providers who provide services to you in connection with this study,,,yes,yes,"Bullet- Health care providers who provide services to you in connection with this study
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"Bullet- Other individuals and organizations that analyze or otherwise use your health information in connection with this study, such as laboratories and other study sites participating in this study",,,yes,yes,"Bullet- Other individuals and organizations that analyze or otherwise use your health information in connection with this study, such as laboratories and other study sites participating in this study
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"Bullet- Other individuals and organizations that assist in determining your health, vital status or contact information should you withdraw from treatment or are otherwise lost to follow-up",,,yes,yes,"Bullet- Other individuals and organizations that assist in determining your health, vital status or contact information should you withdraw from treatment or are otherwise lost to follow-up
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"Will the PHI disclosed per this authorization be redisclosed? Please be aware that after disclosure by the Institution, study doctor, or study staff, there is the possibility that your PHI may be shared with other entities and may no longer be protected by applicable privacy laws and regulations.",,,yes,yes,"Will the PHI disclosed per this authorization be redisclosed? Please be aware that after disclosure by the Institution, study doctor, or study staff, there is the possibility that your PHI may be shared with other entities and may no longer be protected by applicable privacy laws and regulations.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,What rights do you have to review your PHI?,,,yes,yes,"What rights do you have to review your PHI?
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"You have the right to request access to your PHI from the study doctor named above, but to ensure proper evaluation of test results your access to these records may not be allowed until after this study has been completed.",,,yes,yes,"You have the right to request access to your PHI from the study doctor named above, but to ensure proper evaluation of test results your access to these records may not be allowed until after this study has been completed.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"Does this authorization expire and can you revoke authorization for the use and disclosure of your PHI? Your HIPAA Authorization will expire 50 years from the date you sign it unless you revoke (cancel or withdraw) it soonerYou may revoke it by providing written notice to the study doctor that you are revoking the InstitutionÃ¢ÂÂs, study doctorÃ¢ÂÂs and study staffÃ¢ÂÂs authorization to use or disclose your protected health information/PHI. If you revoke this authorization, you will not be allowed to continue your participation in this study and neither the Institution, the study doctor, nor the study staff will be able to use or disclose your PHI generated from this study except to the extent that they or the study sponsor has already relied on this information to conduct the study.",,,yes,yes,"Does this authorization expire and can you revoke authorization for the use and disclosure of your PHI? Your HIPAA Authorization will expire 50 years from the date you sign it unless you revoke (cancel or withdraw) it soonerYou may revoke it by providing written notice to the study doctor that you are revoking the InstitutionÃ¢ÂÂs, study doctorÃ¢ÂÂs and study staffÃ¢ÂÂs authorization to use or disclose your protected health information/PHI. If you revoke this authorization, you will not be allowed to continue your participation in this study and neither the Institution, the study doctor, nor the study staff will be able to use or disclose your PHI generated from this study except to the extent that they or the study sponsor has already relied on this information to conduct the study.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Sharing of Study Data That Identify You: HIPAA Authorization to Use and Disclose Your Protected Health Information,"Can you refuse to sign this authorization? You have the right to refuse to sign this consent, but you will not be allowed to participate in this study. In addition, while your doctor and other treatment providers cannot require you to sign this authorization as a condition of providing general treatment, they may require it for study-related treatment.",,,yes,yes,"Can you refuse to sign this authorization? You have the right to refuse to sign this consent, but you will not be allowed to participate in this study. In addition, while your doctor and other treatment providers cannot require you to sign this authorization as a condition of providing general treatment, they may require it for study-related treatment.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Your Access to and Correction of Study Data that Identifies You:,"You have the right to obtain any initial and updated information about the study data that identifies you, as well as the right according to local law and procedures to require the correction of any errors.",,,yes,yes,"You have the right to obtain any initial and updated information about the study data that identifies you, as well as the right according to local law and procedures to require the correction of any errors.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Your Access to and Correction of Study Data that Identifies You:,"This information, as well as the fact of your participation in this study, can also be provided or made known to your primary physician if you wish.",,,yes,yes,"This information, as well as the fact of your participation in this study, can also be provided or made known to your primary physician if you wish.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Your Access to and Correction of Study Data that Identifies You:,"You can discuss this further with your study doctor, who will be your primary contact person for your access rights.",,,yes,yes,"You can discuss this further with your study doctor, who will be your primary contact person for your access rights.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Collection of Study Data If You End Study Treatments or Completely or Partially End Your Participation in the Study:,"When you stop or complete study treatments, you will begin the last part of the study which follows your continued health condition. This is referred to as the follow-up period. The follow-up period includes the following activities:",,,yes,yes,"When you stop or complete study treatments, you will begin the last part of the study which follows your continued health condition. This is referred to as the follow-up period. The follow-up period includes the following activities:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Collection of Study Data If You End Study Treatments or Completely or Partially End Your Participation in the Study:,"Collection of Follow-up Data: Additional information about your health or health status may be collected in order to properly conduct the study. This information can be referred to as Ã¢ÂÂnecessary follow-up data.Ã¢ÂÂ Collecting necessary follow-up data is important for this study because without it, it may be difficult to assess the safety or effectiveness of the study drug(s) being studied or whether or not other study objectives have been met.",,,yes,yes,"Collection of Follow-up Data: Additional information about your health or health status may be collected in order to properly conduct the study. This information can be referred to as Ã¢ÂÂnecessary follow-up data.Ã¢ÂÂ Collecting necessary follow-up data is important for this study because without it, it may be difficult to assess the safety or effectiveness of the study drug(s) being studied or whether or not other study objectives have been met.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Collection of Study Data If You End Study Treatments or Completely or Partially End Your Participation in the Study:,Follow-up Contact: Study staff may attempt to contact you to request that you come in for follow-up visits or take additional tests in order to preserve the validity or integrity of the study.,,,yes,yes,"Follow-up Contact: Study staff may attempt to contact you to request that you come in for follow-up visits or take additional tests in order to preserve the validity or integrity of the study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Collection of Study Data If You End Study Treatments or Completely or Partially End Your Participation in the Study:,"Use of Third Party Representatives: If your study doctor is unable to locate you during this follow-up period, you authorize your study doctor to disclose your contact information (for example, your name, last known address or other relevant information) to a third party representative for the sole purpose of updating the study doctor and his/her study staff with your current contact information or health status.",,,yes,yes,"Use of Third Party Representatives: If your study doctor is unable to locate you during this follow-up period, you authorize your study doctor to disclose your contact information (for example, your name, last known address or other relevant information) to a third party representative for the sole purpose of updating the study doctor and his/her study staff with your current contact information or health status.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Collection of Study Data If You End Study Treatments or Completely or Partially End Your Participation in the Study:,The representative(s) may be hired directly by the study sponsor.,,,yes,yes,"The representative(s) may be hired directly by the study sponsor.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Collection of Study Data If You End Study Treatments or Completely or Partially End Your Participation in the Study:,The representative(s) and the study sponsor will not contact you or your family members. The representative(s) will share your information only with the study doctor and study staff to help them complete the follow-up portion of the study.,,,yes,yes,"The representative(s) and the study sponsor will not contact you or your family members. The representative(s) will share your information only with the study doctor and study staff to help them complete the follow-up portion of the study.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Use and Collection of Study Data If You End Study Treatments or Completely or Partially End Your Participation in the Study:,"If at any time you would like to end your participation in any of the activities listed above, please notify your study doctor in writing and list the specific activity(ies) that you wish study staff not to perform. Even if you completely end your participation in the study, all study data that has already been collected will continue to be used and processed to maintain the integrity of the research.",,,yes,yes,"If at any time you would like to end your participation in any of the activities listed above, please notify your study doctor in writing and list the specific activity(ies) that you wish study staff not to perform. Even if you completely end your participation in the study, all study data that has already been collected will continue to be used and processed to maintain the integrity of the research.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,This section applies to all samples collected and used for this study as well as additional research/future use samples.,,,yes,yes,"This section applies to all samples collected and used for this study as well as additional research/future use samples.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,"Bullet- The sample encoding procedure is the same as that used for your medical data, and is described in more detail in section Confidentiality of Study Data and Key-coded Data of this form. Samples sent to the sponsor will, therefore, only include your study ID code. Your name and identifying information will remain confidential at all times and will not be revealed in any compilation, study report or publication.",,,yes,yes,"Bullet- The sample encoding procedure is the same as that used for your medical data, and is described in more detail in section Confidentiality of Study Data and Key-coded Data of this form. Samples sent to the sponsor will, therefore, only include your study ID code. Your name and identifying information will remain confidential at all times and will not be revealed in any compilation, study report or publication.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,"Bullet- These samples will be used for the scientific evaluation of this study. Any remaining samples that are available after the study-specific analyses are completed will be known as leftover samples. Any samples that are taken from you for use outside of the study-specific analyses will be known as new samples. Leftover and new samples may be used for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research, except where prohibited by local laws or regulations. This research may involve analyses that reveal genetic information.",,,yes,yes,"Bullet- These samples will be used for the scientific evaluation of this study. Any remaining samples that are available after the study-specific analyses are completed will be known as leftover samples. Any samples that are taken from you for use outside of the study-specific analyses will be known as new samples. Leftover and new samples may be used for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research, except where prohibited by local laws or regulations. This research may involve analyses that reveal genetic information.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,Bullet- All requests for permitted research on leftover and/or new samples that are volunteered under this consent will be reviewed by a diverse committee of senior leaders in Research and Development at BMS or a collaborator to ensure the research supports appropriate and well- defined needs of our scientific research activities and efforts to develop new therapies.,,,yes,yes,"Bullet- All requests for permitted research on leftover and/or new samples that are volunteered under this consent will be reviewed by a diverse committee of senior leaders in Research and Development at BMS or a collaborator to ensure the research supports appropriate and well- defined needs of our scientific research activities and efforts to develop new therapies.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,"Bullet- Samples may be transferred to the research sponsor, its collaborators, research partners, designees, or other relevant third parties who may analyze the samples in connection with this study or other current or future research involving the same drug(s), the same or related therapeutic area, or other relevant health research. These samples may be transferred to individuals or companies located outside of the country/region in which they were taken, when determined by BMS to be important for scientific research and development of therapies. However, the samples and derived data will be kept confidential and secure in accordance with applicable laws regarding Privacy and security. Your samples will not be sold to any other people or companies. You will not be contacted after this study to provide new samples.",,,yes,yes,"Bullet- Samples may be transferred to the research sponsor, its collaborators, research partners, designees, or other relevant third parties who may analyze the samples in connection with this study or other current or future research involving the same drug(s), the same or related therapeutic area, or other relevant health research. These samples may be transferred to individuals or companies located outside of the country/region in which they were taken, when determined by BMS to be important for scientific research and development of therapies. However, the samples and derived data will be kept confidential and secure in accordance with applicable laws regarding Privacy and security. Your samples will not be sold to any other people or companies. You will not be contacted after this study to provide new samples.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,"Bullet- Samples kept for future research by the study sponsor will be stored at the BMS Biorepository in NJ, USA or an independent, BMS-approved storage vendor. The manager of these samples will ensure they are properly used throughout their usable life and will destroy the samples at the end of the scheduled storage period, no longer than fifteen (15) years after the end of the study. Transfers of samples by the study sponsor to third parties will be subject to the third partyÃ¢ÂÂs agreement to establish similar procedures.",,,yes,yes,"Bullet- Samples kept for future research by the study sponsor will be stored at the BMS Biorepository in NJ, USA or an independent, BMS-approved storage vendor. The manager of these samples will ensure they are properly used throughout their usable life and will destroy the samples at the end of the scheduled storage period, no longer than fifteen (15) years after the end of the study. Transfers of samples by the study sponsor to third parties will be subject to the third partyÃ¢ÂÂs agreement to establish similar procedures.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,"Bullet- You will not receive any financial or in kind benefit associated with the development of any new therapies derived from the use of your samples, which may be of commercial value.",,,yes,yes,"Bullet- You will not receive any financial or in kind benefit associated with the development of any new therapies derived from the use of your samples, which may be of commercial value.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,"Bullet- If you withdraw your consent to take part in the study, your samples may still be used for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research. If you do not want your samples used for other current or future research, you may contact the study doctor and have your samples destroyed if they have not yet been used. Any use of your samples, including any information processed from your samples, that occurs before you withdraw your consent will be used by the study sponsor to maintain the integrity of the research.",,,yes,yes,"Bullet- If you withdraw your consent to take part in the study, your samples may still be used for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research. If you do not want your samples used for other current or future research, you may contact the study doctor and have your samples destroyed if they have not yet been used. Any use of your samples, including any information processed from your samples, that occurs before you withdraw your consent will be used by the study sponsor to maintain the integrity of the research.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Regarding Your Samples collected during the study,"A description of this clinical study will be available on as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.",,,yes,yes,"A description of this clinical study will be available on as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Participant Identification Number:,I have received information on the abovementioned study and have had the opportunity to read the information and to ask questions and have received answers.,,,yes,yes,"I have received information on the abovementioned study and have had the opportunity to read the information and to ask questions and have received answers.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Participant Identification Number:,I voluntarily consent to:,,,yes,yes,"I voluntarily consent to:
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Participant Identification Number:,Bullet- Participate in the study,,,yes,yes,"Bullet- Participate in the study
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Participant Identification Number:,Bullet- To follow the instructions provided by my study doctor,,,yes,yes,"Bullet- To follow the instructions provided by my study doctor
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Participant Identification Number:,Bullet- The processing of my personal data derived from the study,,,yes,yes,"Bullet- The processing of my personal data derived from the study
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Participant Identification Number:,Bullet- The transfer of my personal data to countries outside of my own where data protection might differ from the data protection in my country,,,yes,yes,"Bullet- The transfer of my personal data to countries outside of my own where data protection might differ from the data protection in my country
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Participant Identification Number:,"Bullet- The Sponsor and its representatives, as well as Regulatory Authorities, to compare data reported in the study to those contained in my medical records. I consent to this under the condition that the information obtained is not disclosed.",,,yes,yes,"Bullet- The Sponsor and its representatives, as well as Regulatory Authorities, to compare data reported in the study to those contained in my medical records. I consent to this under the condition that the information obtained is not disclosed.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Participant Identification Number:,Bullet- The use and disclosure of my personal health information,,,yes,yes,"Bullet- The use and disclosure of my personal health information
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Participant Identification Number:,I know that at any time and without giving any reason I can withdraw my consent and stop taking part in the study. This will not affect my future treatment and care.,,,yes,yes,"I know that at any time and without giving any reason I can withdraw my consent and stop taking part in the study. This will not affect my future treatment and care.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Participant Identification Number:,I will receive a signed and dated copy of this Participant Information Sheet and Informed Consent Form for my records.,,,yes,yes,"I will receive a signed and dated copy of this Participant Information Sheet and Informed Consent Form for my records.
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
US checkboxes when Additional Research is optional:,"I agree to the use of my study data (including partially or irreversibly anonymized data) and samples (leftover) for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research that is within the scope of the current study protocol; including relevant genetic research.",Yes,,yes,yes,"I agree to the use of my study data (including partially or irreversibly anonymized data) and samples (leftover) for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research that is within the scope of the current study protocol; including relevant genetic research.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
US checkboxes when Additional Research is optional:,"I agree to the use of my study data (including partially or irreversibly anonymized data) and samples (leftover) for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research that is within the scope of the current study protocol; excluding relevant genetic research.",No,,yes,no,"I agree to the use of my study data (including partially or irreversibly anonymized data) and samples (leftover) for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research that is within the scope of the current study protocol; excluding relevant genetic research.
I do not agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",No
US checkboxes when Additional Research is optional:,"I do not want my study data (including partially or irreversibly anonymized data) and samples (leftover) to be used for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research.",No,,yes,no,"I do not want my study data (including partially or irreversibly anonymized data) and samples (leftover) to be used for other current or future research involving the same drug(s), the same or related therapeutic area, or for other relevant health research.
I do not agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",No
Check one about DNA testing:,"I agree to the collection of a blood sample(s) to be used for optional DNA testing described in section 4.0 Biological Samples that relates to this research study.                                                                                                                      Reference: Section 4.0 Biological Samples - This study involves the collection of biological samples, such as blood and urine as described under section 
3 ÂStudy Activities and Time CommitmentÂ. Your samples will be shipped to an accredited central laboratory 
and will be stored there awaiting analysis. The central laboratory being used in this study is Q2 Solutions 
27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA. Biomarker samples will be retained for a minimum 
of 15 years following the completion of the clinical study report to allow sufficient time to complete biomarker 
studies. Other samples will be destroyed once all the laboratory tests have been completed except if you 
agree to the retention of samples for additional research. In that case, please tick the relevant box in the 
informed consent form below about the additional research. You can ask in writing for your samples to be destroyed at any time. However, data already derived from 
your samples will continue to be kept and used for the purposes described in this document. Your data will 
be protected by a code that will not allow BMS or its third parties to know your identity. If you decide to 
leave the study at any time but do not ask for your samples to be destroyed, BMS may continue to use your 
samples for the purposes described in this document. ",Yes,,yes,yes,"I agree to the collection of a blood sample(s) to be used for optional DNA testing described in section 4.0 Biological Samples that relates to this research study.                                                                                                                      Reference: Section 4.0 Biological Samples - This study involves the collection of biological samples, such as blood and urine as described under section 
3 ÂStudy Activities and Time CommitmentÂ. Your samples will be shipped to an accredited central laboratory 
and will be stored there awaiting analysis. The central laboratory being used in this study is Q2 Solutions 
27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA. Biomarker samples will be retained for a minimum 
of 15 years following the completion of the clinical study report to allow sufficient time to complete biomarker 
studies. Other samples will be destroyed once all the laboratory tests have been completed except if you 
agree to the retention of samples for additional research. In that case, please tick the relevant box in the 
informed consent form below about the additional research. You can ask in writing for your samples to be destroyed at any time. However, data already derived from 
your samples will continue to be kept and used for the purposes described in this document. Your data will 
be protected by a code that will not allow BMS or its third parties to know your identity. If you decide to 
leave the study at any time but do not ask for your samples to be destroyed, BMS may continue to use your 
samples for the purposes described in this document. 
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Check one about DNA testing:,"I do not agree to the optional blood sample for DNA collection described in section 4.0 Biological Samples that relates to this research study.                                                                                                                                                Reference: Section 4.0 Biological Samples - This study involves the collection of biological samples, such as blood and urine as described under section 
3 ÂStudy Activities and Time CommitmentÂ. Your samples will be shipped to an accredited central laboratory 
and will be stored there awaiting analysis. The central laboratory being used in this study is Q2 Solutions 
27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA. Biomarker samples will be retained for a minimum 
of 15 years following the completion of the clinical study report to allow sufficient time to complete biomarker 
studies. Other samples will be destroyed once all the laboratory tests have been completed except if you 
agree to the retention of samples for additional research. In that case, please tick the relevant box in the 
informed consent form below about the additional research. You can ask in writing for your samples to be destroyed at any time. However, data already derived from 
your samples will continue to be kept and used for the purposes described in this document. Your data will 
be protected by a code that will not allow BMS or its third parties to know your identity. If you decide to 
leave the study at any time but do not ask for your samples to be destroyed, BMS may continue to use your 
samples for the purposes described in this document. ",No,,yes,no,"I do not agree to the optional blood sample for DNA collection described in section 4.0 Biological Samples that relates to this research study.                                                                                                                                                Reference: Section 4.0 Biological Samples - This study involves the collection of biological samples, such as blood and urine as described under section 
3 ÂStudy Activities and Time CommitmentÂ. Your samples will be shipped to an accredited central laboratory 
and will be stored there awaiting analysis. The central laboratory being used in this study is Q2 Solutions 
27027 Tourney Road, Suite 2E, Valencia, CA 91355, USA. Biomarker samples will be retained for a minimum 
of 15 years following the completion of the clinical study report to allow sufficient time to complete biomarker 
studies. Other samples will be destroyed once all the laboratory tests have been completed except if you 
agree to the retention of samples for additional research. In that case, please tick the relevant box in the 
informed consent form below about the additional research. You can ask in writing for your samples to be destroyed at any time. However, data already derived from 
your samples will continue to be kept and used for the purposes described in this document. Your data will 
be protected by a code that will not allow BMS or its third parties to know your identity. If you decide to 
leave the study at any time but do not ask for your samples to be destroyed, BMS may continue to use your 
samples for the purposes described in this document. 
I do not agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",No
Signatures,Participant name,,Nafisa Ali,yes,yes,"Participant name
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Nafisa Ali
Signatures,Participant date,,2/5/2023,yes,yes,"Participant date
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",2/5/2023
Signatures,Participant signature,,Nafisa Ali,yes,yes,"Participant signature
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Signatures,Study Personnel Performing Consent Print name,,Kamini U,yes,yes,"Study Personnel Performing Consent Print name
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Kamini U
Signatures,Study Personnel Performing Consent date,,2/5/2023,yes,yes,"Study Personnel Performing Consent date
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",2/5/2023
Signatures,Study Personnel Performing Consent signature,,Kamini U,yes,yes,"Study Personnel Performing Consent signature
I agree to the above statement",Study,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
19.0 Short Message Service (SMS) Reminder Service,,,,yes,yes,"
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"As part of your participation in this study, you are asked to attend scheduled study appointments and complete study-related tasks. To help you to remember your obligations, you can enroll in an optional service to receive text/SMS messages.",,,yes,yes,"As part of your participation in this study, you are asked to attend scheduled study appointments and complete study-related tasks. To help you to remember your obligations, you can enroll in an optional service to receive text/SMS messages.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"If you elect to receive text/SMS messages on your mobile device, please expect the following:",,,yes,yes,"If you elect to receive text/SMS messages on your mobile device, please expect the following:
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"Bullet- Standard text message rates may apply. Your mobile carrier may charge for text messages sent and received, please check your texting plan to confirm.",,,yes,yes,"Bullet- Standard text message rates may apply. Your mobile carrier may charge for text messages sent and received, please check your texting plan to confirm.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,Bullet- Provide your mobile phone number to your study team and advise them if your mobile phone number changes while participating in the POETYK PSO study.,,,yes,yes,"Bullet- Provide your mobile phone number to your study team and advise them if your mobile phone number changes while participating in the POETYK PSO study.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,Bullet- Any identifiable information you provide in connection with this service will be shared only with your study team.,,,yes,yes,"Bullet- Any identifiable information you provide in connection with this service will be shared only with your study team.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"Bullet- Your mobile number will be securely stored and kept confidential. The SponsorÃ¢ÂÂs third-party vendor, Neonstone, will use your mobile number for purposes only described in this consent form and nothing else (e.g., marketing or sale to further vendors).",,,yes,yes,"Bullet- Your mobile number will be securely stored and kept confidential. The SponsorÃ¢ÂÂs third-party vendor, Neonstone, will use your mobile number for purposes only described in this consent form and nothing else (e.g., marketing or sale to further vendors).
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"All mobile text/SMS messages received will be study-related only. You can request access to your personal data held about you in connection with this service, correct any inaccuracies, and stop at any time by advising your study team.",,,yes,yes,"All mobile text/SMS messages received will be study-related only. You can request access to your personal data held about you in connection with this service, correct any inaccuracies, and stop at any time by advising your study team.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"If you choose not to or change your mind about using this service, your decision will not affect your participation in the study or your medical care.",,,yes,yes,"If you choose not to or change your mind about using this service, your decision will not affect your participation in the study or your medical care.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"Once you have completed the study, your mobile number will be automatically removed. If at any time you choose to leave the study before your final visit, the study team will manually remove your mobile number and you will no longer receive text/SMS messages.",,,yes,yes,"Once you have completed the study, your mobile number will be automatically removed. If at any time you choose to leave the study before your final visit, the study team will manually remove your mobile number and you will no longer receive text/SMS messages.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"In accordance to the EUÃ¢ÂÂs General Data Protection Regulation (GDPR) approved and adopted by the EU Parliament and Council in December 2015 enforceable May 25 2018., the name and address of the data controller is:",,,yes,yes,"In accordance to the EUÃ¢ÂÂs General Data Protection Regulation (GDPR) approved and adopted by the EU Parliament and Council in December 2015 enforceable May 25 2018., the name and address of the data controller is:
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,Bristol-Myers Squibb,,,yes,yes,"Bristol-Myers Squibb
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"Route 206 & Province Line Road Princeton, NJ 08543, USA",,,yes,yes,"Route 206 & Province Line Road Princeton, NJ 08543, USA
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"By providing your mobile phone number below, you agree and acknowledge that Neonstone (a third-party vendor on behalf of Bristol Meyers Squib) will send study-related text/SMS messages, associated with the POETYK PSO study, to your mobile device. You also understand that these text messages will be sent in line with your planned appointment schedule. If you choose to receive text/SMS messages, you understand that you can stop them by contacting your study team. If you have any questions, please contact your study team.",,,yes,yes,"By providing your mobile phone number below, you agree and acknowledge that Neonstone (a third-party vendor on behalf of Bristol Meyers Squib) will send study-related text/SMS messages, associated with the POETYK PSO study, to your mobile device. You also understand that these text messages will be sent in line with your planned appointment schedule. If you choose to receive text/SMS messages, you understand that you can stop them by contacting your study team. If you have any questions, please contact your study team.
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"Yes, I would like to receive text/SMS messages that will remind me of upcoming appointments and procedures",Yes,,yes,yes,"Yes, I would like to receive text/SMS messages that will remind me of upcoming appointments and procedures
I agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",Yes
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,"No, I choose not receive text/SMS messages.",No,,yes,no,"No, I choose not receive text/SMS messages.
I do not agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",No
Optional Consent Form for Study-Related Reminder Mobile Text/SMS Messages,Mobile Phone Number:,789211xxxx,,yes,no,"Mobile Phone Number:
I do not agree to the above statement",Certificate,"{'Drug': 'BMS-986165', 'Disease': 'Plaque Psoriasis', 'country': 'United States of America'}",789211xxxx
